Indiana 2026 Regular Session

Indiana House Bill HB1399

Introduced
1/8/26  

Caption

Ephedrine and pseudoephedrine products.

Impact

The implementation of HB1399 will significantly alter existing laws regarding drug sales, particularly for ephedrine and pseudoephedrine, which are often associated with the production of methamphetamine. By creating an electronic logging system, the legislation aims to enhance the tracking of purchases, thereby aiding in the prevention of drug misuse and fostering better compliance with state and federal regulations. This could lead to a decrease in unlawful activities associated with these drugs, protecting public health and safety while promoting responsible sales practices in pharmacies.

Summary

House Bill 1399 establishes a comprehensive regulatory framework for the sale and monitoring of ephedrine and pseudoephedrine products in Indiana. It requires the state police department to manage an electronic logging system that records and monitors real-time purchases of these substances. The aim is to prevent illegal purchases and facilitate investigations into related illegal activities. The bill mandates that manufacturers validate their contracts with licensed vendors for electronic tracking, thus standardizing how these substances are monitored across the state. It also removes earlier restrictions, allowing individuals without an established relationship with a pharmacy to purchase these products under specific conditions.

Contention

Notably, the bill has raised some points of contention among stakeholders. Supporters argue that the electronic logging system will enhance law enforcement capabilities and allow for a more responsible distribution of controlled substances. However, some critics express concerns that the new regulations may impose restrictions that could inconvenience legitimate consumers who require these medications for health reasons. There is also an ongoing debate about the balance between regulation and access, particularly concerning individuals who may find it challenging to establish a relationship with pharmacies due to health or mobility issues.

Companion Bills

No companion bills found.

Previously Filed As

IN SB0306

Film and media production tax credit.

IN SB0297

Film and media production tax credit.

IN SB0478

Craft hemp flower and THC products.

IN SB0322

Sale of tobacco products.

IN SB0425

Energy production zones.

IN HB1426

Liability shield products.

IN HB1650

Vapor products and e-liquids matters.

IN SB0138

Sale of low THC products to persons less than 21.

IN SB0386

Community corrections programs.

IN SB0231

Various corrections matters.

Similar Bills

IN SB0262

INSPECT program.

MS SB2733

NPLEx; require manufacturers of certain pseudoephedrine or ephedrine products to pay fees to support the administration of.

MS HB1463

Pseudoephedrine; require manufacturers to pay fees to National Association of Drug Diversion Investigators to support NPLE.

MO SB1069

Limits the sale or purchase of certain drugs

MI HB4948

Controlled substances: other; sentencing guidelines for retail sale of products containing ephedrine or pseudoephedrine; modify. Amends sec. 13m, ch. XVII of 1927 PA 175 (MCL 777.13m). TIE BAR WITH: HB 4947'25

MI HB4947

Health: pharmaceuticals; manufacturers of products containing ephedrine or pseudoephedrine; require to participate in a national logging system. Amends secs. 7340 & 7340a of 1978 PA 368 (MCL 333.7340 & 333.7340a).

MO SB726

Limits the sale or purchase of certain drugs

MO HB1962

Modifies provisions relating to limits on selling or purchasing certain drugs